Menu
← Oncology Approval Tracker
FDA DECISION ·
Pepaxto
melphalan flufenamide with dexamethasone · Oncopeptides
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after four or more prior lines and resistance to a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody. FDA withdrew approval on February 23, 2024.
LAMPGEN ANALYSIS
Why it matters
The historical authorization defined a heavily treated, triple-class-refractory population. The later FDA withdrawal changed its regulatory status.
What research teams should watch
Preserve individual drug class exposure and distinguish the historical decision from current treatment options.
PRIMARY RECORDS